Affymetrix, Illumina and Life Technologies Hold Entrenched Leadership Positions in Key Gene Expression Profiling Market Segments Revealed in New Report from Percepta Associates

Healthy Growth Projected in Three of Nine Segments Analyzed in New Gene Expression Profiling Life Science Dashboard™

CARLSBAD, Calif.--(BUSINESS WIRE)--Percepta Associates is pleased to announce the launch of the 2012 Gene Expression Profiling, Series 4 Life Science Dashboard™ market research report, providing rapid access to actionable key market indicators for the gene expression profiling market. The 2012 Dashboard draws comparisons to market data reported in Percepta's 2008 and 2010 Gene Expression Profiling Dashboards, including market size, competitive shares, growth rates, customer satisfaction/propensity to switch, and end-user practices, in an 'at a glance' easy to understand format, allowing suppliers of products for gene expression profiling to easily track the effectiveness of marketing strategies and tactics over time. Market segments analyzed, including several new areas of focus, are as follows:

“Several gene expression profiling market segments continue to experience rapid growth, with annual rates exceeding 10% in two key segments. Even as next-generation sequencing methods rapidly enter the mainstream, our data shows that expression profiling methods will continue to be necessary tools in the advancement of life science research”

• Differential gene expression studies using multiplex endpoint PCR
• Digital gene expression/molecular barcodes
• Microarray-based gene expression studies (including bead arrays)
• qRT-PCR (cDNA template) using gene specific fluorescent probes
• qRT-PCR (cDNA template) using non-specific SYBR Green
• Northern blot analysis
• Serial analysis of gene expression (SAGE) studies
• Transcriptome studies using tiling arrays
• Transcriptome studies via (RNA-seq) short-read sequencing

Life Technologies (NASDAQ:LIFE) is the leading supplier in five of the nine segments analyzed, with one entrenched leadership position. Affymetrix (NASDAQ:AFFX) and Illumina (NASDAQ:ILMN) hold dominant positions in two of the segments not led by Life Technologies. Bio-Rad (NYSE:BIO) was also cited among the leading suppliers in several segments. Furthermore, findings reveal that over half of respondents, in six of the nine segments expressed an interest in switching primary suppliers. “Several gene expression profiling market segments continue to experience rapid growth, with annual rates exceeding 10% in two key segments. Even as next-generation sequencing methods rapidly enter the mainstream, our data shows that expression profiling methods will continue to be necessary tools in the advancement of life science research,” said Alison Rowland, Principal at Percepta.

The 2012 Gene Expression Profiling, Series 4 Life Science Dashboard™ also analyzes current primary and secondary applications for each market segment, uncovering key downstream application changes observed over the past four years. Specific product and protocol improvement needs that may drive customer switching behavior are cited by respondents and revealed as verbatim comments in this report.

The 2012 Gene Expression Profiling Dashboard™ was developed from responses to a 23-question survey completed by 460 scientists predominantly located in North America and Europe. These respondents perform gene expression profiling methods on a regular basis.

To view Gene Expression Profiling Dashboard™ Series 4 sample data and the survey questionnaire visit:

http://www.perceptaassociates.com/publications/12_gene_expression_overview.shtml

About Percepta

Founded in 2005 in Carlsbad, California Percepta Associates is a specialized consultancy providing expert market research, strategic business planning, portfolio management, product and corporate branding and marketing communications services to life science research suppliers globally. For more information visit: www.perceptaassociates.com or call 760 431 6300.

For more information visit www.perceptaassociates.com.